Search Within

Hematologic Malignancies Research

  1. "Sean Devlin"
  2. "2019"
Formats
  1. Meeting Abstract (8)
  2. Journal Article (3)
Groups
  1. Biostatistics Service (11)
  2. Center for Hematologic Malignancies (11)
  3. Department of Medicine (11)
  4. Epidemiology and Biostatistics (11)
  5. Hematologic Malignancies, Division of (11)
  6. Survivorship Research (8)

More Groups

People
  1. Sean Devlin (11)
  2. Carl Landgren (6)
  3. Gunjan Shah (6)
  4. Michael Scordo (6)
  5. Sergio Giralt (6)
  6. Alexander Lesokhin (5)

More People

Years
  1. 2019 (11)
Publications
  1. Blood (6)
  2. Biology of Blood and Marrow Transplantation (1)
  3. Blood Advances (1)
  4. JCI Insight (1)
  5. Journal of Clinical Oncology (1)
  6. PLoS ONE (1)
Publishers
  1. American Society of Hematology (7)
  2. Amer Soc Clinical Investigation Inc (1)
  3. American Society of Clinical Oncology (1)
  4. Elsevier Inc. (1)
  5. Public Library of Science (1)

Results (11)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • VTE rates and safety analysis of newly diagnosed multiple myeloma patients receiving carfilzomib-lenalidomide-dexamethasone (KRD) with or without rivaroxaban prophylaxis
    Meeting Abstract

    Piedra, K. M.; Hassoun, H.; Buie, L. W.; Devlin, S. M.; Flynn, J.; Hultcrantz, M.; Lesokhin, A. M.; Lu, S. X.; Mailankody, S.; Shah, U. A.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • Comparing gradings of immune effector cells toxicities: Application of ASTCT consensus grading system and implications for clinical management
    Meeting Abstract

    Pennisi, M.; Jain, T.; Mead, E.; Santomasso, B.; Silverberg, M. L.; Batlevi, Y.; Shouval, R.; Maloy, M. A.; Devlin, S. M.; Batlevi, C. L.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • EASIX and modified-EASIX are early predictors of severe cytokine release syndrome and neurotoxicity in patients treated with chimeric antigen receptor T cells
    Meeting Abstract

    Pennisi, M.; Sanchez-Escamilla, M.; Flynn, J.; Maloy, M. A.; Silverberg, M. L.; Batlevi, Y.; Shouval, R.; Batlevi, C. L.; Brentjens, R. J.; Devlin, S. M.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • Long-term sustained minimal residual disease (MRD) negativity in multiple myeloma patients treated with lenalidomide maintenance therapy: A clinical and correlative phase 2 study
    Meeting Abstract

    Landgren, O.; Mastey, D.; Lesokhin, A. M.; Smith, E. L.; Shah, U. A.; Mailankody, S.; Hultcrantz, M.; Hassoun, H.; Lu, S. X.; Salcedo, M.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • Hematological count recovery in patients undergoing treatment with chimeric antigen receptor T cells (CAR T)
    Meeting Abstract

    Jain, T.; Knezevic, A.; Pennisi, M.; Ruiz, J. D.; Devlin, S. M.; Maloy, M. A.; Halton, E.; Diamonte, C.; Scordo, M.; Sauter, C. S.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • Double-unit cord blood (CB) transplantation (dCBT) supplemented with haplo-identical CD34+ cells may be associated with enhanced neutrophil recovery but successful myeloid bridging is strongly influenced by haplo CD34+ cell dose and haplo-winning CB unit HLA-match
    Meeting Abstract

    Politikos, I.; Devlin, S. M.; Mazis, C.; Maloy, M. A.; Naputo, K.; Afuye, A.; Avecilla, S. T.; Castro-Malaspina, H.; Dahi, P. B.; Giralt, S. A.; more...
    Biology of Blood and Marrow Transplantation (2019)

    Fulltext@MSK | Save
  • Weekly carfilzomib, lenalidomide, dexamethasone and daratumumab (wKRd-D) combination therapy provides unprecedented MRD negativity rates in newly diagnosed multiple myeloma: A clinical and correlative phase 2 study
    Meeting Abstract

    Landgren, O.; Hultcrantz, M.; Lesokhin, A. M.; Mailankody, S.; Hassoun, H.; Smith, E. L.; Shah, U. A.; Lu, S. X.; Mastey, D.; Salcedo, M.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • Ixazomib and dexamethasone in high risk smoldering multiple myeloma: A clinical and correlative pilot study
    Meeting Abstract

    Mailankody, S.; Salcedo, M.; Tavitian, E.; Korde, N.; Lendvai, N.; Hassoun, H.; Lesokhin, A. M.; Lahoud, O. B.; Smith, E. L.; Hultcrantz, M.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Minimal residual disease negativity in multiple myeloma is associated with intestinal microbiota composition
    Journal Article

    Pianko, M. J.; Devlin, S. M.; Littmann, E. R.; Chansakul, A.; Mastey, D.; Salcedo, M.; Fontana, E.; Ling, L.; Tavitian, E.; Slingerland, J. B.; more...
    Blood Advances (2019)

    Fulltext@MSK | Save
  • Safety and tolerability of conditioning chemotherapy followed by CD19-targeted CAR T cells for relapsed/refractory CLL
    Journal Article

    Geyer, M. B.; Riviere, I.; Senechal, B.; Wang, X.; Wang, Y.; Purdon, T. J.; Hsu, M.; Devlin, S. M.; Palomba, M. L.; Halton, E.; more...
    JCI Insight (2019)

    Fulltext@MSK | Save